BDA
Director Trades
| Date | Director | Value |
|---|
Company News
Cannabis Access Clinics looks to aid Australian patient access to medical cannabis
The theory behind medical cannabis is that it has the potential to soothe many of today’s ailments, with illnesses such as epilepsy, multiple sclerosis (MS) and post-traumatic stress disorder (PTSD) all in the firing line to be remedied. The reality, however, is far less idealistic and must include aspects such as overall cost, patient qualification […]
Bod Australia issues first MediCabilis scripts under Europe’s largest medicinal cannabis project
Cannabis-focused healthcare company Bod Australia (ASX: BDA) has issued the first prescriptions for its MediCabilis product to UK patients participating in Europe’s largest medicinal cannabis registry. Project Twenty21 aims to generate the largest body of evidence in the UK to date for the efficacy of medicinal cannabis, based on up to 20,000 patients suffering from […]
Bod Australia receives record order for cannabinoid and hemp products
It’s been a busy week for Bod Australia (ASX: BDA) with the company following up its first UK MediCabilis prescriptions with news it had received a record $1.43 million purchase order from Health and Happiness Group to sell its cannabinoid (CBD) and hemp products. Most of the order is for Bod’s CBD products including its […]
Bod Australia receives major capital boost via Health & Happiness Group’s innovation arm
Cannabis-focused healthcare company Bod Australia (ASX: BDA) has struck an exclusive agreement with investment fund NewH2 owned by Hong Kong-listed Health & Happiness Group (H&H). Under the deal, NewH2 will make $5.5 million strategic investment in Bod – effectively giving NewH2 a 17.64% stake and the ability to appoint two directors to Bod’s board. The deal means […]
Bod Australia reveals ‘significant’ growth in medicinal cannabis prescriptions, more to come
Bod Australia (ASX: BDA) revealed this morning it has experienced “significant growth” in prescriptions for its medicinal cannabis product, with this growth expected to expand further once numerous applications have been granted. During June and July, Bod filled 220 prescriptions for its 5% CBD MediCabilis product – up substantially from the 55 prescriptions distributed between […]
Bod Australia’s cannabis oil to be used in landmark PTSD trial
Cannabis-focused healthcare company Bod Australia (ASX: BDA) has announced it will supply its pharmaceutical-grade cannabis extract MediCabilis for a landmark 12-month trial related to post traumatic stress disorder (PTSD). The $491 drug will be prescribed to 300 participants in oil form by approved prescribers in a network managed by Bod’s research partner Cannabis Access Clinics […]
Clinical trial highlights tolerability of Bod Australia’s medicinal cannabis product
A phase one clinical trial of a sublingual cannabis wafer developed by Bod Australia (ASX: BDA) has highlighted the tolerability and superiority of the product and deemed it safe for human consumption. The experimental trial – based around an open label, randomised, placebo-controlled, four-way crossover study of 24 healthy volunteers – was designed to determine […]
Bod Australia posts record quarterly revenue thanks to new products, distribution deals
Skincare and health products developer Bod Australia (ASX: BDA) has posted a record revenue of $1.22 million for the last quarter of 2018, underpinned by an expansion of its product range, new distribution deals and strong product uptake. The figure includes sales of $766,000 for the period and represents a 260% increase on first quarter […]
Bod Australia gets green light to export growing medicinal cannabis product range
Cosmetics and natural medicines company Bod Australia (ASX: BDA) has received the green light to export its patented sublingual form of medicinal cannabis after gaining an export listing on the Australian Register of Therapeutic Goods, operated by the TGA. Bod says its “cannabis wafer” provides an easy to deliver, pharmaceutical-grade medicinal cannabis product with higher […]
Chemist Warehouse adds Bod Australia’s cannabis oil MediCabilis to its shelves
Australia’s adoption of medicinal cannabis has taken another step forward after Bod Australia (ASX: BDA) announced it has begun dispensing MediCabilis, its proprietary cannabis oil, via Chemist Warehouse stores nationwide. Chemist Warehouse is currently ranked as Australia’s largest pharmacy retailer with 450 store locations and employs around 15,000 staff, based in all major cities in […]
Company Videos
No videos found.